Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2025. The report serves as a transaction notification regarding a specific event involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a single executive compensation transaction.
- Transaction Type: Vesting of a Deferred Investment Award.
- Instrument: Ordinary shares of 31 1/4 pence each (ISIN: GB00BN7SWP63).
- Volume: 17,182.417 notional Ordinary Shares.
- Price: £14.4300 per share.
- Settlement: Cash payment of £247,942.28 (less applicable tax withholding).
Material Changes
The filing details the vesting on February 18, 2025, of 50% of an award originally made on February 18, 2021, under the GlaxoSmithKline Deferred Investment Award Programme. This is an initial notification of the transaction and does not represent a material change in the company's overall financial position or operations.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a specific equity-based compensation event.
Key Facts for Investor Verification
- Verify the identity of the recipient: Tony Wood, Chief Scientific Officer.
- Confirm the transaction date: February 18, 2025.
- Note that the award was settled in cash rather than physical shares.
- Recognize that this filing does not contain quarterly or annual financial performance data.